Several other analysts have also recently commented on AQST. Wedbush restated a buy rating and issued a $37.00 price target on shares of Aquestive Therapeutics in a report on Monday. Zacks Investment Research upgraded shares of Aquestive Therapeutics from a hold rating to a buy rating and set a $6.00 price objective on the stock in a report on Monday, November 11th. Finally, HC Wainwright reiterated a buy rating and set a $14.00 price objective (up from $12.00) on shares of Aquestive Therapeutics in a report on Monday. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company has an average rating of Buy and an average price target of $18.40.
NASDAQ AQST opened at $8.75 on Tuesday. The business’s 50-day moving average price is $5.14 and its 200 day moving average price is $4.19. Aquestive Therapeutics has a twelve month low of $2.95 and a twelve month high of $10.00. The company has a market capitalization of $221.48 million, a PE ratio of -3.13 and a beta of 2.70.
Aquestive Therapeutics Company Profile
Aquestive Therapeutics, Inc, a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery in the United States and internationally.
Read More: Put Option
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.